Home › Research › Inflammation and the immune system
The gut microbiome in Alzheimer's disease: what we know and what remains to be explored
Chandra S, Sisodia SS, Vassar RJ.. Molecular neurodegeneration, 2023-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD), the most common cause of dementia, results in a sustained decline in cognition. There are currently few effective disease modifying therapies for AD, but insights into the mechanisms that mediate the onset and progression of disease may lead to new, effective therapeutic strategies. Amyloid beta oligomers and plaques, tau aggregates, and neuroinflammation play a critical role in neurodegeneration and impact clinical AD progression.
What this study adds
Evidence grade: Low
This is a narrative review. This review discusses the gut microbiome as a possible upstream modulator of amyloid, tau and neuroinflammation in Alzheimer's disease, while noting there are currently few effective disease-modifying therapies. It offers no confirmed treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chandra, S., Sisodia, S. S., & Vassar, R. J. (2023). The gut microbiome in Alzheimer's disease: what we know and what remains to be explored. Molecular neurodegeneration. https://doi.org/10.1186/s13024-023-00595-7
Vancouver
Chandra S, Sisodia SS, Vassar RJ. The gut microbiome in Alzheimer's disease: what we know and what remains to be explored. Molecular neurodegeneration. 2023. doi:10.1186/s13024-023-00595-7. PMID: 36721148.
BibTeX
@article{chandra2023-36721148,
author = {Chandra, S. and Sisodia, S. S. and Vassar, R. J.},
title = {{The gut microbiome in Alzheimer's disease: what we know and what remains to be explored}},
journal = {Molecular neurodegeneration},
year = {2023},
doi = {10.1186/s13024-023-00595-7},
pmid = {36721148},
url = {https://doi.org/10.1186/s13024-023-00595-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- There are currently few effective disease modifying therapies for AD, but insights into the mechanisms that mediate the onset and progression of disease may lead to new, effective therapeutic strategies.
- Amyloid beta oligomers and plaques, tau aggregates, and neuroinflammation play a critical role in neurodegeneration and impact clinical AD progression.
- The upstream modulators of these pathological features have not been fully clarified, but recent evidence indicates that the gut microbiome (GMB) may have an influence on these features and therefore may influence AD progression in human patients.
- In this review, we summarize studies that have identified alterations in the GMB that correlate with pathophysiology in AD patients and AD mouse models.
Why it matters
This review discusses the gut microbiome as a possible upstream modulator of amyloid, tau and neuroinflammation in Alzheimer's disease, while noting there are currently few effective disease-modifying therapies. It offers no confirmed treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 275 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 55.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 5 / 6 | Cited 20.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 4 / 4 | Cited 236 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Robert J. Vassar: h-index 73 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Chicago: institution h-index 1,769 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36721148) |
| Free to read | 2 / 2 | Free to read |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13024-023-00595-7
- PubMed: 36721148
- Original source →
- Free full text: Molecular Neurodegeneration →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Inflammation and the immune system from nearby years
Also in Inflammation and the immune system
138 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.